Canon Medical: AI-Based Image Reconstruction Technology Now Available for 96 Percent of Procedures Using 1.5T MR

February 1, 2021

Canon Medical is bringing the power of accessible artificial intelligence (AI) for improved image quality to more patients with expanded clinical indications for 1.5T MR.

Advanced intelligent Clear-IQ Engine (AiCE) Deep Learning Reconstruction (DLR) can now be used for 96 percent of all procedures using the Vantage Orian 1.5T MR system*, expanding from previously FDA-cleared brain and knee indications to a vastly larger number of clinical indications, from prostate to shoulders, including all joints, cardiac, pelvis, abdomen and spine.

AiCE was trained using vast amounts of high-quality image data, and features a deep learning neural network that can reduce noise and boost signal to quickly deliver sharp, clear and distinct images, allowing clinicians to boost image quality, performance, productivity and throughput on a whole new scale.

“As we continue to expand the availability of AiCE, Canon Medical is ensuring that the maximum number of patients can benefit from the advanced images, expanded clinical capabilities and seamless integration that this advanced AI technology provides,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc. “In today’s environment, making images easy to read and acquire is more important than ever, and this is the latest demonstration of our commitment to offering accessible AI that clinicians can use to make the greatest impact on patient care.”

With the expansion of indications, Canon Medical’s AiCE Challenge has also expanded. To see if you can tell the difference between 1.5T AiCE and traditional 3T image quality, take the AiCE Challenge today.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”